Нарушения функции щитовидной железы и сердечно-сосудистая система

Полный текст:


Обзор посвящен влиянию тиреотоксикоза и гипотиреоза на сердечно-сосудистую систему и риск смертности от сердечно-сосудистых заболеваний. Также обсуждаются особенности заместительной терапии препаратами тиреоидных гормонов у пациентов с кардиальной патологией.

Список литературы

1. Aghini-Lombardi F., Di Bello V., Talini E. et al. Early textural and functional alterations of left ventricular myocardium in mild hypothyroidism // Eur. J. Endocrinol. 2006. V. 155. P. 3–9.

2. Asvold B.O., Bjoro T., Nilsen T.I. et al. Association between blood pressure and serum TSH concentration within the reference range: a population-based study // J. Clin. Endocrinol. Metab. 2007. V. 92. P. 841–845.

3. Åsvold B.O., BjØro T., Nilsen T.I. et al. Thyrotropin Levels and Risk of Fatal Coronary Heart Disease. The HUNT Study // Arch. Intern. Med. 2008. V. 168. P. 855–860.

4. Auer J.A., Scheibner P., Mische T. et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation // Am. Heart. J. 2001. V. 142. P. 838–842.

5. Bar-Sela S., Ehrenfeld M., Eliakim M. Arterial embolism in thyrotoxicosis with atrial fibrillation // Arch. Intern. Med. 1981. V. 141. P. 1191–1192.

6. Bauer D.C., Ettinger B., Browner W.S. Thyroid function and serum lipids in older women: a population-based study // Am. J. Med. 1998. V.104. P. 546–551.

7. Bibbins-Domingo K., Chertow G.M., Fried L.F. et al. Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study // Arch. Intern. Med. 2006. V. 166. P. 1396–1402.

8. Bindels A.J., Westendorp R.G., Frolich M. et al. The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need for case-finding? // Clin. Endocrinol. (Oxf.). 1999. V.50. P. 217–220.

9. Biondi B., Cooper D.S. The Clinical Significance of Subclinical Thyroid Dysfunction // Endocrin. Rev. 2008. V. 29. P. 76–131.

10. Biondi B. Cardiovascular effects of mild hypothyroidism // Thyroid. 2007. V. 17. P. 625–630.

11. Biondi B., Fazio S., Palmieri E.A. et al. Mortality in elderly patients with subclinical hyperthyroidism // Lancet. 2002. V. 359. P. 799–800.

12. Biondi B., Klein I. Hypothyroidism as a risk factor for cardiovascular disease // Endocrin. 2004. V. 24. P. 1–13.

13. Biondi B., Palmieri E.A., Klain M. et al. Subclinical hyperthyroidism: clinical features and treatment options // Eur. J. Endocrinol. 2005. V. 152. P. 1–9.

14. Canaris G.J., Manovitz N.R., Mayor G., Ridgway E.C. The Colorado thyroid disease prevalence study // Arch. Intern. Med. 2000. V. 160. P. 526–534.

15. Cappola A.R. Subclinical thyroid dysfunction and the heart // J. Clin. Endocrinol. Metab. 2007. V. 92. P. 3404–3405.

16. Cappola A.R., Fried L.P., Arnold A.M. et al. Thyroid Status, Cardiovascular Risk, and Mortality in Older Adults // JAMA. 2006. V. 295. P. 1033–1041.

17. Cappola A.R., Ladenson P.W. Hypothyroidism and atherosclerosis // J. Clin. Endocrinol. Met. 2003. V. 88. P. 2438–2444.

18. Clyde P.W., Harari A.E., Getka E.J. et al. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial // JAMA. 2003. V. 290. P. 2952–2958.

19. Cooper D.S. Approach to the patient with subclinical hyperthyroidism // J. Clin. Endocrinol. Metab. 2007. V. 92. P. 3–9.

20. Cooper D.S., Doherty G.M., Haugen B.R. et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer // Thyroid. 2006. V. 16. P. 109–142.

21. Croteau W., Davey J.C., Galton V.A., St Germain D.L. Cloning of the mammalian type II iodothyronine deiodinase: a selenoprotein differentially expressed and regulated in human and rat brain and other tissues // J. Clin. Invest. 1996. V.98. P. 405–417.

22. Escobar-Morreale H.F., Botella-Carretero J.I. Thyroid Hormone Replacement Therapy in Primary Hypothyroidism: A Randomized Trial Comparing L-Thyroxine plus Liothyronine with L-Thyroxine Alone // Ann. Intern. Med. 2005. V. 142. P. 412–424.

23. Fazio S., Palmieri E.A., Lombardi G., Biondi B. Effects of thyroid hormone on the cardiovascular system // Rec. Progr. Horm. Research. 2004. V. 59. P. 31–50.

24. Foldes J., Banos C., Winkler G. Subclinical hypothyroidism and arteriosclerosis // Orv. Hetil. 2004. V. 145(31). P. 1601–1607.

25. Franklyn J.A., Maisonneuve P., Sheppard M.C. et al. Mortality after the treatment of hyperthyroidism with radioactive iodine // N. Engl. J. Med. 1998. V. 338. P. 712–718.

26. Gilligan D.M., Ellenbogen K.A., Epstein A.E. The management of atrial fibrillation // Am. J. Med. 1996. V. 101. P. 413–421.

27. Goldman M.B., Maloof F., Monson R.R. et al. Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women // Am. J. Epidemiol. 1988. V. 127. P. 969–980.

28. Haentjens P., van Meerhaeghe A. et al. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess allcause mortality based on time-to-event data from cohort studies // Eur. J. Endocrinol. 2008. V. 159(3). P. 329–341.

29. Hak A.E., Pols H.A., Visser T.J. et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study // Ann. Intern. Med. 2000. V. 132. P. 270–278.

30. Hall P., Lundell G., Holm L.E. Mortality in patients treated for hyperthyroidism with iodine-131 // Acta Endocrinol.1993. V. 28. P. 230–234.

31. Hueston W.J., Pearson W.S. Subclinical hypothyroidism and the risk of hypercholesterolemia // Ann. Fam. Med. 2004. V. 2. P. 351–355.

32. Iqbal A., Schirmer H., Lunde P. et al. Thyroid stimulating hormone and left ventricular function // J. Clin. Endocrinol. Met. 2007. V. 92. P. 3504–3510.

33. John P., Walsh J.P., Alexandra P. et al. Subclinical Thyroid Dysfunction as a Risk Factor for Cardiovascular Disease // Arch. Intern. Med. 2005. V. 165. P. 2467–2472.

34. Kahaly G.J. Cardiovascular and atherogenic aspects of subclinical hypothyroidism // Thyroid. 2000. V. 10. P. 665–679.

35. Kahaly G.J., Dillmann W.H. Thyroid hormone action in the heart // Endocrin. Rev. 2005. V. 26. P. 704–728.

36. Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system // N. Engl. J. Med. 2001. V. 344. P. 501–509.

37. Klein I., Danzi S. Thyroid disease and the heart // Circulat. 2007. V. 116. P. 1725–1735.

38. Krahn A.D., Klein G.J., Kerr C.R. et al. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators // Arch. Intern. Med. 1996. V. 156. P. 2221–2224.

39. Mandel S.J., Brent G.A., Larsen P.R. Levothyroxine therapy in patients with thyroid disease // Ann. Intern. Med. 1993. V. 119. P. 492–502.

40. Mattace-Raso F.U., van der Cammen T.J., Hofman A. et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study // Circulation. 2006. V. 113. P. 657–663.

41. Mercuro G., Panzuto M.G., Bina A. et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring // J. Clin. Endocrinol. Metab. 2000. V. 85. P. 159–164.

42. Nagasaki T., Inaba M., Kumeda Y. et al. Increased pulse wave velocity in subclinical hypothyroidism // J. Clin. Endocrinol. Metab. 2006. V. 91. P. 154–158.

43. Nakazawa H.K., Sakurai K., Hamada N. et al. Management of atrial fibrillation in the post-thyrotoxic state // Am. J. Med. 1982. V. 72. P. 903–906.

44. Nordyke R.A, Gilbert F.I.Jr., Harada A.S. Graves’ disease. Influence of age on clinical findings // Arch. Intern. Med. 1988. V. 148. P. 626–631.

45. Parle J.V., Maisonneuve P., Sheppard M.C. et al. Prediction of allcause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study // Lancet. 2001. V. 358. P. 861–865.

46. Petersen P., Hansen J.M. Stroke in thyrotoxicosis with atrial fibrillation // Stroke. 1988. V. 19. P. 15–18.

47. Ripoli A., Pingitore A., Favilli B. et al. Does subclinical hypothyroidism affect cardiac pump performance? Evidence from a magnetic resonance imaging study // J. Am. Coll. Cardiol. 2005. V. 45. P. 439–445.

48. Roberts C.G.P., Ladenson P.W. Hypothyroidism // Lancet. 2004. V. 363. P. 793-803.

49. Rodondi N., Bauer D.C., Cappola A.R. et al. Subclinical Thyroid Dysfunction, Cardiac Function, and the Risk of Heart Failure. The Cardiovascular Health Study // J. Am. Col. Cardiology. 2008. V. 14. P. 1152-1159.

50. Rodondi N., Newman A.B., Vittinghoff E. et al. Subclinical Hypothyroidism and the Risk of Heart Failure, Other Cardiovascular Events, and Death // Arch. Intern. Med. 2005. V. 165. P. 2460–2466.

51. Roos A.; Linn-Rasker S.P., van Domburg R.T. et al. The Starting Dose of Levothyroxine in Primary Hypothyroidism Treatment. A Prospective, Randomized, Double-blind Trial. // Arch. Intern. Med. 2005. V. 165. P. 1714–1720.

52. Sawin C.T., Geller A., Wolf P.A. et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons // N. Engl. J. Med. 1994. V. 331. P. 1249–1252.

53. Sawka A.M., Gerstein H.C., Marriott M.J. et al. Does a combination regimen of thyroxine (T4) and 3,5,3’-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial // J. Clin. Endocrinol. Metab. 2003. V. 88. P. 4551–4555.

54. Sgarbi J.A., Villaca F., Garbeline B. et al. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism on clinical and heart abnormalities // J. Clin. Endocrinol. Metab. 2003. V. 88. P. 1672–1677.

55. Shargorodsky M., Serov S., Gavish D. et al. Long-term thyrotropinsuppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma // Thyroid. 2006. V. 16. P. 381–386.

56. Siegmund W., Spieker K., Weike A.I. et al. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio

57. : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism // Clin. Endocrinol. (Oxf.). 2004. V. 60. P. 750–757.

58. Singer D.E,. Albers G.W,. Dalen J.E. et al. Antithrombotic Therapy in Atrial Fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy // Chest. 2004. V. 126. P. 429S–456S.

59. Singh S., Duggal J., Molnar J. et al. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis // Intern. J. Cardiol. 2008. V. 125. P. 41–48.

60. Smit J.W., Eustatia-Rutten C.F., Corssmit E.P. et al. Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study // J. Clin. Endocrinol. Metab. 2005. V. 90. P. 6041–6047.

61. Smith R.N., Taylor S.A., Massey J.C. Controlled clinical trial of combined triiodothyronine and thyroxine in the treatment of hypothyroidism // Br. Med. J.1970. V. 4.P. 145–148.

62. Surks M.I., Ortiz E., Daniels G.H. et al. Subclinical thyroid disease. Scientific review and guidelines for diagnosis and management // J. Am. Med. Assoc. 2004. V. 291. P. 228–238.

63. Tenerz A., Forberg R., Jansson R. Is a more active attitude warranted in patients with subclinical thyrotoxicosis? // J. Intern. Med. 1999. V. 228. P. 229–233.

64. Tunbridge W.M., Evered D.C., Hall R. et al. Lipid profiles and cardiovascular disease in the Whickham area with particular reference to thyroid failure // Clin. Endocrinol. (Oxf.). 1977. V. 7. P. 495–508.

65. Vanderpump M.P., Tunbridge W.M., French J.M. et al. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community // Thyroid. 1996. V. 6. P. 155–160.

66. Völzke H., Schwahn C., Wallaschofski H. et al. Review: the association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship? // J. Clin. Endocrinol. Metab. 2007. V. 92. P. 2421–2429.

67. Walsh J.P., Shiels L., Lim E.M. et al. Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism // J. Clin. Endocrinol. Metab. 2003. V. 88. P. 4543–4550.

68. Yazici M., Gorgulu S., Sertbas Y. et al. Effects of thyroxin therapy on cardiac function in patients with subclinical hypothyroidism: index of myocardial performance in the evaluation of left ventricular function // Intern. J. Cardiol. 2004. V. 95. P. 135–143.

69. Zile M.R., Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure. Part II: causal mechanisms and treatment // Circulat. 2002. V. 105. P. 1503–1508.

70. Zindrou D., Taylor K.M., Bagger J.P. Excess coronary artery bypass graft mortality among women with hypothyroidism // Ann. Thorac. Surg. 2002. V. 74. P. 2121–2125.

Для цитирования:

Troshina E.A., Yukina M.Y., Ogneva N.A., Mazurina N.V. Нарушения функции щитовидной железы и сердечно-сосудистая система. Клиническая и экспериментальная тиреоидология. 2010;6(1):12-19.

For citation:

., ., ., . Thyroid function disorders and cardiovascular system. Clinical and experimental thyroidology. 2010;6(1):12-19. (In Russ.)

Просмотров: 9

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1995-5472 (Print)
ISSN 2310-3787 (Online)